References
- Strang J, Volkow ND, Degenhardt L, et al. Opioid use disorder. Nat Rev Dis Primers. 2020;6(1):3. doi: 10.1038/s41572-019-0137-5
- Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020;87(1):82–88. doi: 10.1016/j.biopsych.2019.06.020
- Chappuy M, Trojak B, Nubukpo P, et al. Prolonged-release buprenorphine formulations: perspectives for clinical practice. Therapies. 2020;75(5):397–406. doi: 10.1016/j.therap.2020.05.007
- Rolland B, Trojak B, Nourredine M, et al. Determinants of interest in extended-released buprenorphine: a survey among 366 French patients treated with buprenorphine or methadone. Drug Alcohol Depend. 2021;220:108492. doi: 10.1016/j.drugalcdep.2020.108492
- Larance B, Degenhardt L, Grebely J, et al. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction. 2020;115(7):1295–1305. doi: 10.1111/add.14941
- Pascual FS, Muñoz A, Oraa R, et al. Perception of a new prolonged-release buprenorphine formulation in patients with opioid use disorder: the predepo study. Eur Addict Res. 2022;28(2):143–154. doi: 10.1159/000520091
- Vorspan F, Hjelmström P, Simon N, et al. What place for prolonged-release buprenorphine depot-formulation Buvidal in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine. Expert Opin Drug Deliv. 2019 Sep;16(9):907–914. doi: 10.1080/17425247.2019.1649252
- Soyka M. Novel long-acting buprenorphine medications for opioid dependence: current update. Pharmacopsychiatry. 2021 Jan;54(1):18–22. doi: 10.1055/a-1298-4508
- European Medicines Agency (EMA). Sixmo®: overview. [Updated 2023 Feb 20; cited 2023 Feb 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo
- National Health Service (NHS). Prescription data. [cited 2024 Jan 2]. Available from: https://www.nhsbsa.nhs.uk/prescription-data
- Health and Social Care Northern Ireland. General Pharmaceutical Services and Prescribing Statistics. [cited 2024 Jan 2]. Available from: https://bso.hscni.net/directorates/operations/family-practitioner-services/directorates-operations-family-practitioner-services-information-unit/general-pharmaceutical-services-and-prescribing-statistics/
- National Health Service Wales. Prescription data extracts. [cited 2024 Jan 2]. Available from: https://nwssp.nhs.wales/ourservices/primary-care-services/general-information/data-and-publications/
- Scottish Public Health Observatory (ScotPHO). Opioid Substitution Therapy (OST) Drug Prescribing. [cited 2024 Jan 2]. Available from: https://www.scotpho.org.uk/risk-factors/drugs/data/prescribing-for-drug-use/
- Drug Research Network Scotland (DRNS). Long acting injectable buprenorphine: knowledge exchange event. [cited 2024 Jan 2]. Available from: https://drns.ac.uk/long-acting-injectable-buprenorphine-knowledge-exchange-event/
- Community Pharmacy News. Pharmacy pilots ‘game changing’ buprenorphine injection. [Updated 2021 Jul 8 cited 2021 Jul 8]. Available from: https://www.chemistanddruggist.co.uk/CD005980/Pharmacy-pilots-game-changing-buprenorphine-injection;
- Scottish Government. Positive report on the use of Buvidal in prisons. [Updated 2021 Jul 7; cited 2021 Jul 7]. Available from: https://www.gov.scot/news/positive-report-on-the-use-of-buvidal-in-prisons/
- Matheson C, Foster R, Schofield J, et al. Long-acting depot buprenorphine in people who are homeless: views and experiences. J Subst Abuse Treat. 2022;139:108781. doi: 10.1016/j.jsat.2022.108781
- Partanen A, Alho H, Kuussaari K, et al. Opioidikorvaushoidossa olevien määrä on jatkanut kasvuaan [The number of people on opioid substitution treatment has continued to rise in 2019]. Suom Lääkäril. 2022 [cited 2024 Jan 2];77:e32696. Available from: www.laakarilehti.fi/e32696
- Finlex. Sosiaali- ja terveysministeriön asetus opioidiriippuvaisten vieroitus- ja korvaushoidosta opioidilääkkeillä [Decree of the Ministry of Social Affairs and Health on withdrawal and substitution treatment of opioid addiction with opioid medicine]. [Updated 2023 Mar 29; cited 2023 Mar 29].
- Council of Europe. Council for penological co-operation (pc-cp). Replies to the questionnaire on mental disorders and disabilities of persons in penal detention). [Updated 2021 May 10; cited 2021 May 10]. Available from: https://rm.coe.int/pc-cp-2021-4-e-replies-to-questionnaire-on-mental-health-in-prisons/1680a25a8c
- EMCDDA. Finland, Country Report; 06/06/2019. [cited 2024 Jan 2]. Available from: https://www.emcdda.europa.eu/publications/country-drug-reports/2019/finland_en
- Ministerio de Sanidad. BIFIMED: Buscador de la Información sobre la situación de financiación de los medicamentos - Nomenclátor de DICIEMBRE – 2023/Buprenorfina. [ BIFIMED: Search engine for information on the financing situation of medicines - Nomenclature of DECEMBER – 2023/Buprenorphine]. [cited 2024 Jan 2]. Available from: https://www.sanidad.gob.es/profesionales/medicamentos.do?metodo=verDetalle&cn=725941
- Ministerio de Sanidad y Seguridad Social. «BOE» núm. 274, de 16 de noviembre de 1977 Referencia: BOE-A-1977-27160. [cited 2024 Jan 2]. Available from: https://www.boe.es/buscar/pdf/1977/BOE-A-1977-27160-consolidado.pdf
- Observatoire Français des Drogues et Tendances addictives (OFDT). Tableau de bord « Traitements de substitution aux opioïdes » 2020 [”Opioid Substitution Treatments” 2020 scoreboard]. [Updated 2020 Jan 9; cited 2020 Jan 9]. Available from: https://www.ofdt.fr/publications/collections/bilans/tableau-de-bord-traitements-de-substitution-aux-opioides-2020/
- Haute Autorité de Santé (HAS). Buvidal. [Updated 2021 Mar 22; cited 2021 Mar 22]. Available from: https://www.has-sante.fr/jcms/p_3244165/fr/buvidal-buprenorphine;
- Barnett A, Savic M, Lintzeris N, et al. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia. Drug Alcohol Depend. 2021;227:108959. doi: 10.1016/j.drugalcdep.2021.108959
- Ministère de la Santé et de la Prévention. Bulletin officiel « Santé, Protection sociale, Solidarité » N° 24. [Updated 2022 Nov 30; cited 2022 Nov 30]. Available from: https://sante.gouv.fr/fichiers/bo/2022/2022.24.sante.pdf;
- EMCDDA. Opioid agonist treatment – the current situation in Europe. European Drug Report 2023. [Updated 2023 Jun 16; cited 2023 Jun 16]. Available from: https://www.emcdda.europa.eu/publications/european-drug-report/2023/opioid-agonist-treatment_en;
- Selin J, Hakkarainen P, Partanen A, et al. From political controversy to a technical problem? Fifteen years of opioid substitution treatment in Finland. Int J Drug Policy. 2013;24(6):e66–72. doi: 10.1016/j.drugpo.2013.08.007
- van Amsterdam J, van den Brink W, Pierce M. Explaining the differences in opioid overdose deaths between Scotland and England/wales: implications for European opioid policies. Eur Addict Res. 2021;27(6):399–412. doi: 10.1159/000516165
- Ling W, Nadipelli VR, Aldridge AP, et al. Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study. J Addict Med. 2020;14(5):e233–e240. doi: 10.1097/ADM.0000000000000647
- Serpelloni G, Gomma M, Genetti B, et al. Italy’s electronic health record system for opioid agonist treatment. J Subst Abuse Treat. 2013 Aug;45(2):190–195. doi: 10.1016/j.jsat.2013.02.001
- Michels SH II, Gerlach R, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduct J. 2007;4(1):5. doi: 10.1186/1477-7517-4-5
- Griffiths PN, Seyler T, De Morais JM, et al. Opioid problems are changing in Europe with worrying signals that synthetic opioids may play a more significant role in the future. Addiction. 2023. doi: 10.1111/add.16420